Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does...
One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT)...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart...
The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021.

News | Left Atrial Appendage (LAA) Occluders | August 16, 2021
August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage...
Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

News | EP Lab | July 29, 2021
July 29, 2021 – Results of the STROKE-VT trial shows direct oral anticoagulants (DOACs) are more effective than aspirin...
A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19.

A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19. Researchers believe statins, which attach to the ACE2 receptors, may block the virus from attaching to these same receptors. 

News | Coronavirus (COVID-19) | July 21, 2021
July 21, 2021 — In a new study from University of California San Diego School of Medicine, researchers have confirmed...
New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. Getty Images
 

Feature | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly...
Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.
 

News | Stents | June 30, 2021
June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug...
Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

News | Coronavirus (COVID-19) | June 28, 2021
June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in...
Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR)...
FDA Clears Pradaxa as First Oral Anticoagulant for Children. Dabigatran, has been cleared by the FDA
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients.

News | Heart Failure | May 18, 2021
May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a...
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021

Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.

News | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly...
The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.
News | Peripheral Artery Disease (PAD) | May 17, 2021
May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the...
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 

Feature | EP Lab | May 16, 2021 | By Dave Fornell, Editor
May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...